Nomura update "Statistically significant results – will progress to a Phase IIb"
Nomura Update "F12 – good progress, expect a F13 EMA decision"
Nomura Update "Funds to be used for further clinical development"
Nomura Quick Note: "Launches US Phase III trial for EPP treatment"
Nomura Update "Considerable upside should NSV trials be successful"
Investors' Blog Posts
We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...Read More
Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...Read More
Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...Read More